Gilead Sciences, Inc.  

(Public, NASDAQ:GILD)   Watch this stock  
Find more results for gild
69.10
+0.93 (1.36%)
Real-time:   12:33PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 68.34 - 69.89
52 week 46.70 - 84.88
Open 69.32
Vol / Avg. 8.83M/19.12M
Mkt cap 106.27B
P/E 38.00
Div/yield     -
EPS 1.82
Shares 1.54B
Beta 0.58
Inst. own 94%
May 19, 2014
Gilead Sciences at UBS Global Life Sciences Conference Add to calendar
May 13, 2014
Gilead Sciences at Bank of America Merrill Lynch Health Care Conference Add to calendar
May 7, 2014
Gilead Sciences 2014 Annual Shareholder Meeting Add to calendar
Apr 22, 2014
Q1 2014 Gilead Sciences Earnings Release - 4:05PM EDT - Add to calendar
Apr 22, 2014
Q1 2014 Gilead Sciences Earnings Conference Call - 1:15PM EDT - Add to calendar
Mar 3, 2014
Gilead Sciences at Cowen Health Care Conference - Webcast
Feb 26, 2014
Gilead Sciences at RBC Capital Markets Healthcare Conference - Webcast
Feb 12, 2014
Gilead Sciences at Leerink Swann Global Healthcare Conference - Webcast
Feb 11, 2014
Gilead Sciences at Biotechnology Industry Organization CEO & Investor Conference - Webcast
Feb 4, 2014
Q4 2013 Gilead Sciences Earnings Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 25.22% 27.29%
Operating margin 38.37% 40.39%
EBITD margin - 43.46%
Return on average assets 14.04% 13.98%
Return on average equity 28.53% 29.75%
Employees 6,100 -
CDP Score - -

Address

333 LAKESIDE DR
FOSTER CITY, CA 94404
United States - Map
+1-650-5743000 (Phone)
+1-650-5789264 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead�s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Asia Pacific. The Company�s products include Atripla, Truvada, Viread, Complera/Eviplera, Emtriva, Hepsera, Letairis, Ranexa, Lexiscan/Rapiscan, AmBisome, Vistide, Macugen, Cayston and Tamiflu. In January 2012, the Company acquired Pharmasset, Inc. On February 8, 2013, its subsidiary, acquired YM BioSciences Inc.

Officers and directors

John C. Martin Ph.D. Chairman of the Board, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
John F. Milligan Ph.D. President, Chief Operating Officer
Age: 52
Bio & Compensation  - Reuters
Robin L. Washington Chief Financial Officer, Executive Vice President
Age: 50
Bio & Compensation  - Reuters
Norbert W. Bischofberger Ph.D. Executive Vice President - Research and Development, Chief Scientific Officer
Age: 57
Bio & Compensation  - Reuters
Gregg H. Alton Executive Vice President - Corporate and Medical Affairs
Age: 47
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Paul Carter Executive Vice President
Bio & Compensation  - Reuters
Per Wold-Olsen Director
Age: 66
Bio & Compensation  - Reuters
John F. Cogan Jr,Ph.d Independent Director
Age: 62
Bio & Compensation  - Reuters
Etienne F. Davignon Independent Director
Age: 80
Bio & Compensation  - Reuters
Carla A. Hills Independent Director
Age: 79
Bio & Compensation  - Reuters